Understanding the Basics of Repligen (RGEN) Stock

We're taking a closer look at Repligen today, as the chatter surrounding the stock has increased notably in the last few weeks. Today, its shares moved 19.0% compared to 0.0% for the S&P 500. Increased investor interest and volatility surrounding the stock are not reason enough to buy in -- you should first perform your own due diligence. Here are some figures that can get you started:

  • Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally.

  • Repligen has moved -27.0% over the last year compared to 10.0% for the S&P 500 -- a difference of -37.0%

  • RGEN has an average analyst rating of buy and is -30.88% away from its mean target price of $196.54 per share

  • Its trailing 12 month earnings per share (EPS) is $2.42

  • Repligen has a trailing 12 month Price to Earnings (P/E) ratio of 56.1 while the S&P 500 average is 15.97

  • Its forward earnings per share (EPS) is $2.29 and its forward P/E ratio is 59.3

  • RGEN has a Price to Earnings Growth (PEG) ratio of -47.77, which shows the company is fairly valued compared to its earnings.

  • The company has a Price to Book (P/B) ratio of 3.84 in contrast to the S&P 500's average ratio of 2.95

  • Repligen is part of the Health Care sector, which has an average P/E ratio of 24.45 and an average P/B of 4.16

  • Repligen has on average reported free cash flows of $58.34 Million over the last four years, during which time they have grown by an an average of 28.5%

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.